Ferroptosis Regulator Information
General Information of the Ferroptosis Regulator (ID: REG10185)
Full List of the Ferroptosis Target of This Regulator and Corresponding Disease/Drug Response(s)
ARF6
can regulate the following target(s), and cause disease/drug response(s). You can browse detail information of target(s) or disease/drug response(s).
Browse Target
Browse Disease
Long-chain-fatty-acid--CoA ligase 4 (ACSL4) [Driver]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [1] | |||
Target for Ferroptosis | Driver | |||
Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Ras signaling pathway | hsa04014 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
HPDE6-C7 cells | Normal | Homo sapiens | CVCL_0P38 |
AsPC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 | |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
BxPC-3 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
SW1990 cells | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |
Capan-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0237 | |
MIA PaCa-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0428 | |
Response regulation | ARF6, functioned as a downstream of Kras/ERK signaling pathway, could promote proliferation and Warburg effect in pancreatic cancer cells. ARF6 decreased ACSL4 protein level and this effect endowed pancreatic cancer cells to a status that sensitized to oxidative stress. | |||
Unspecific Target [Unspecific Target]
In total 1 item(s) under this target | ||||
Experiment 1 Reporting the Ferroptosis Target of This Regulator | [2] | |||
Responsed Disease | Gastric cancer | ICD-11: 2B72 | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Ras signaling pathway | hsa04014 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
GES-1 cells | Normal | Homo sapiens | CVCL_EQ22 |
SGC-7901 cells | Gastric carcinoma | Homo sapiens | CVCL_0520 | |
BGC-823 cells | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
AGS cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0139 | |
MKN45 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0434 | |
SNU-1 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0099 | |
MGC-803 cells | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
Response regulation | ARF6, as a downstream effector of the Kirsten rat sarcoma viral oncogene (Kras)/extracellular signal-regulated kinases (ERK) signaling pathway, may increase proliferation and induce the Warburg effect in gastric cancer (GC) cells. ARF6 may control capecitabine resistance via several routes. | |||
Pancreatic cancer [ICD-11: 2C10]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [1] | |||
Target Regulator | ADP-ribosylation factor 6 (ARF6) | Protein coding | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Ras signaling pathway | hsa04014 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
HPDE6-C7 cells | Normal | Homo sapiens | CVCL_0P38 |
AsPC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0152 | |
PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
BxPC-3 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0186 | |
SW1990 cells | Pancreatic adenocarcinoma | Homo sapiens | CVCL_1723 | |
Capan-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0237 | |
MIA PaCa-2 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0428 | |
Response regulation | ARF6, functioned as a downstream of Kras/ERK signaling pathway, could promote proliferation and Warburg effect in pancreatic cancer cells. ARF6 decreased ACSL4 protein level and this effect endowed pancreatic cancer cells to a status that sensitized to oxidative stress. | |||
Gastric cancer [ICD-11: 2B72]
In total 1 item(s) under this disease | ||||
Experiment 1 Reporting the Ferroptosis-centered Disease Response | [2] | |||
Target Regulator | ADP-ribosylation factor 6 (ARF6) | Protein coding | ||
Pathway Response | Ferroptosis | hsa04216 | ||
Ras signaling pathway | hsa04014 | |||
Cell Process | Cell ferroptosis | |||
Cell proliferation | ||||
In Vitro Model |
GES-1 cells | Normal | Homo sapiens | CVCL_EQ22 |
SGC-7901 cells | Gastric carcinoma | Homo sapiens | CVCL_0520 | |
BGC-823 cells | Gastric carcinoma | Homo sapiens | CVCL_3360 | |
AGS cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0139 | |
MKN45 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0434 | |
SNU-1 cells | Gastric adenocarcinoma | Homo sapiens | CVCL_0099 | |
MGC-803 cells | Gastric mucinous adenocarcinoma | Homo sapiens | CVCL_5334 | |
Response regulation | ARF6, as a downstream effector of the Kirsten rat sarcoma viral oncogene (Kras)/extracellular signal-regulated kinases (ERK) signaling pathway, may increase proliferation and induce the Warburg effect in gastric cancer (GC) cells. ARF6 may control capecitabine resistance via several routes. | |||
References